替普瑞酮辅助治疗老年幽门螺杆菌阳性胃溃疡疗效分析

目的探讨替普瑞酮辅助治疗老年幽门螺杆菌（Hp）阳性胃溃疡患者的疗效。 方法选取2019年6月至2021年6月在谷城县人民医院确诊的100例Hp感染伴胃溃疡患者，其中50例予四联疗法治疗（对照组），余50例在其基础上联合口服替普瑞酮（观察组），均持续治疗2周。比较两组临床疗效、胃蛋白酶原Ⅰ（PGⅠ）、胃泌素-17、白细胞介素-8（IL-8）和肿瘤坏死因子-α（TNF-α）水平和不良反应。计数资料比较采用χ²检验，计量资料比较采用t检验。 结果两组患者治疗总有效率的差异无统计学意义（χ²=0.298，P>0.05）。治疗后，两组患者胃蛋白酶原Ⅰ和胃泌素-17均较治疗前升高（观察组：t=15.789、24.325，对照组：t=12.612、13.452，P<0.05），且观察组较对照组升高更加显著（t=2.299、6.050，P<0.05或0.01）；两组TNF-α和IL-8均较治疗前降低（观察组：t=51.065、16.228，对照组：t=24.701、6.819，P<0.05），且观察组较对照组降低更加显著（t=29.360、13.767，P<0.01）。治疗期间两组不良反应发生率的差异无统计学意义（χ²=0.444，P>0.05）。 结论对于老年Hp阳性胃溃疡患者，替普瑞酮辅助治疗可降低患者胃黏膜损伤水平和炎症水平，有利于患者康复。

Efficacy of teprenone in the adjuvant treatment for elderly patients with Helicobacter pylori positive gastric ulcer

ObjectiveTo observe the efficacy of teprenone in the adjuvant treatment of elderly patients with Helicobacter pylori (Hp) positive gastric ulcer. MethodsA total of 100 patients with Hp infection and gastric ulcer diagnosed in Gucheng County People's Hospital from June 2019 to June 2021 were selected. Among them, 50 patients were treated with quadruple therapy (control group), and the remaining 50 patients were treated with oral tiprenone on the basis of quadruple therapy (observation group), and the both treatments lasted for 2 weeks. Clinical efficacy, pepsinogen Ⅰ(PGⅠ), gastrin-17, interleukin-8 (IL-8), tumor necrosis factor -α (TNF-α) and adverse reactions were compared between the two groups. Chi-square test was used for comparison between counting data, and t test was used for comparison between quantitative data. ResultsThere was no significant difference in total effective rate between the two groups (χ²=0.298, P > 0.05). After treatment, the levels of PGⅠand gastrin-17 in both groups were higher than those before treatment (observation group: t=15.789, 24.325, control group: t=12.612, 13.452, P < 0.05), and the two indexes in the observation group were increased more significantly than those in the control group (t=2.299, 6.050, P < 0.05 or P < 0.01). TNF-α and IL-8 in two groups were decreased compared with before treatment (observation group: t=51.065, 16.228, control group: t=24.701, 6.819, P < 0.05), and the two indexes in observation group were decreased more significantly than those in the control group (t=29.360, 13.767, P < 0.01). There was no significant difference in the incidence of adverse reactions between the two groups (χ²=0.444, P > 0.05). ConclusionFor elderly patients with HP positive gastric ulcer, tipreidone can reduce gastric mucosal injury and inflammation level, which is beneficial to patients' recovery.